Mar 16, 2009 - XenoPort, Inc. announced today that the U.S. FDA has accepted for review the new drug application (NDA) filed by GlaxoSmithKline (GSK) for Solzira (gabapentin enacarbil) Extended Release Tablets in the United States as a potential treatment for moderate-to-severe primary Restless Legs Syndrome (RLS).
The details can be read here.
No comments:
Post a Comment